Biotech
Candid Therapeutics
Candid Therapeutics raises $370M Series A at $1.2B valuation
San Francisco, CASeptember 9, 20241 min read
Latest funding
$370M
Valuation
$1.2B
Latest Round
Series A
Employees
70+
Candid Therapeutics: Series A Funding Round
Candid Therapeutics has successfully raised $370M in Series A funding, reaching a valuation of $1.2B.
Company Overview
Developing novel therapeutics for autoimmune diseases
Funding Details
The Series A round was led by Venrock, with participation from Fairmount, TCGX.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 70+
- Category: Biotech
Investment
Candid Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Venrock: Verified investor in Series A
- Fairmount: Verified investor in Series A
- TCGX: Verified investor in Series A
Company Info
Headquarters
San Francisco, CA
Founded
2023
Team Size
70+
Last Round
$370M(Sep 2024)
Investors (3)
V
VenrockLeadLead Investor
Verified investor in Series A
F
FairmountInvestor
Verified investor in Series A
T
TCGXInvestor
Verified investor in Series A
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started